{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-026908","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2024-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.253958+00:00","generated_at":"2026-05-31T09:02:43.093702+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NRx Pharma narrows Q2 net loss to $7.9M; secures $10.8–16.3M convertible debt for NDAs","bullets":["Q2 net loss $7.9M vs $8.7M YoY; six-month net loss $14.4M vs $19.8M.","Secured $10.8–16.3M convertible debt from Anson Funds; retired Streeterville debt at litigation discount.","Plans to file NDAs for NRX-100 (IV ketamine) and NRX-101 for bipolar depression in Q4 2024.","HOPE Therapeutics audit complete; spinout SEC filing planned this quarter.","Cash $1.9M at June 30; new funding expected to support filings and operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-026908","json":"https://secwatch.observer/filing/0001437749-24-026908.json","markdown":"https://secwatch.observer/filing/0001437749-24-026908.md","text":"https://secwatch.observer/filing/0001437749-24-026908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774924026908/0001437749-24-026908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774924026908/nrxp20240814d_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:02:43.093702+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}